NRXS Stock Summary and Trading Ideas (Neuraxis | AMEX:NRXS)

Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Neuraxis trades on the AMEX stock market under the symbol NRXS.

As of July 28, 2026, NRXS stock price declined to $6.46 with 68,861 million shares trading.

NRXS has a beta of 0.60, meaning it tends to be less sensitive to market movements. NRXS has a correlation of 0.01 to the broad based SPY ETF.

NRXS has a market cap of $80.00 million. This is considered a Micro Cap stock.

Last quarter Neuraxis reported $2 million in Revenue and -$.18 earnings per share. This beat revenue expectation by $157,000 and exceeded earnings estimates by $.01.

The top ETF exchange traded funds that NRXS belongs to (by Net Assets): VTI, VXF, IWC.

NRXS has outperformed the market in the last year with a return of +133.2%, while the SPY ETF gained +17.5%. However, in the most recent history, NRXS shares have underperformed the stock market with its stock returning -20.5% in the last 3 month period and -6.1% for the last 2 week period, while SPY has returned +3.9% and -1.1%, respectively.

NRXS support price is $6.50 and resistance is $6.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NRXS shares will trade within this expected range on the day.